MARKER GENE TECHNOLOGIES INC
Biotech · Private
High-content and high-throughput screening systems for discovering therapeutics targeting neurodegenerative and lysosomal storage diseases
- Grants
- $2.6M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 9
- 6 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20152016201720182019
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Targeted Pharmacological Chaperones for Neurological Diseases | $224,593 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeted Pharmacological Chaperones for Neurological Diseases | $224,593 | |
| Federal grant | Department of Health and Human Services · Phase II · Live-Cell Assays of ER and Golgi Enzyme Activities | $631,417 | |
| Federal grant | Department of Health and Human Services · Phase II · Live-Cell Assays of ER and Golgi Enzyme Activities | $1,097,123 | |
| Federal grant | Department of Health and Human Services · Phase II · Live-Cell Assays of ER and Golgi Enzyme Activities | $366,935 | |
| Federal grant | Department of Health and Human Services · Phase II · Live-Cell Assays of ER and Golgi Enzyme Activities | $98,771 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2557 | Hennepin Life Sciences | — | $1.9M |
| 2558 | Biomakers, Inc. | — | $1.5M |
| 2559 | Resilience Therapeutics, Inc. | — | $1.4M |
| 2560 | MARKER GENE TECHNOLOGIES INC | — | — |
| 2561 | Mountain Valley MD Holdings Inc. | — | $1.4M |
| 2562 | STATEGICS, INC. | — | — |
| 2563 | Sentia Medical Sciences, Inc. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Targeted Peptide Conjugatesgranted
- Intracellular Organelle Peptide Targeted Enzyme Substratesgranted
- Targeted Pharmacological Chaperonesgranted
- Intracellular Organelle Peptide Targeted Enzyme Substratesgranted
- Enzyme Substrates For Visualizing Acidic Organellesgranted
- Targeted Pharmacological Chaperonesgranted
- Reagents And Methods For Direct Labeling Of Nucleotidesapplication
- Synthetic luciferase gene and proteinapplication
- Targeted pharmacological chaperones, uses thereof for the treatment of disease and methods of preparation of the sameapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.